ArticleDiagnostic pathology2025
Novel immunohistochemical assay utilizing the INSM1 (SP493) antibody demonstrates high specificity and sensitivity in detecting primary neuroendocrine lung neoplasms.
Article in Diagnostic pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAbout 15–20% of lung neoplasms are of neuroendocrine origin. In addition to evaluation of morphological features, these neoplasms can be identified by immunohistochemistry (IHC) using antibodies against neuroendocrine markers such as synaptophysin, chromogranin A, and neural cell adhesion molecule, CD56. Recent studies have shown that insulinoma-associated protein 1 (INSM1) is increasingly used as a diagnostic marker for neoplasms of neuroendocrine origin, as it is highly sensitive and specific. The primary focus of this study was to evaluate the sensitivity and specificity of a recently developed assay that uses a new INSM1 (SP493) antibody for detecting primary neuroendocrine lung neoplasms and to compare this IHC assay with currently used neuroendocrine markers.
methodTissue microarrays containing 391 lung neoplasms were stained with INSM1 (SP493) antibody, INSM1 (MRQ-70) antibody, CONFIRM anti-Synaptophysin (SP11) antibody, anti-Chromogranin A (LK2H10) antibody, and CD56 (MRQ-42) antibody on BenchMark ULTRA instruments using OptiView IHC DAB Detection Kit or ultraView Universal DAB Detection Kit using manufacturer’s recommended protocols. Sensitivity, specificity, and accuracy were calculated for each biomarker.
resultsThe sensitivity and specificity of the new assay using INSM1 (SP493) antibody for detecting primary lung neoplasms with neuroendocrine differentiation were 96.8% and 92.3%, respectively. Comparable results were seen for the lung neoplastic cases stained with INSM1 (MRQ-70) antibody, yielding a sensitivity of 94.9% and specificity of 94.1%. In contrast, the anti-Chromogranin A (LK2H10) antibody and CD56 (MRQ-42) antibody showed considerably lower sensitivities. The sensitivity was 78.7% for the anti-Chromogranin A (LK2H10) antibody and 85.4% for the CD56 (MRQ-42) antibody. However, the specificities of anti-Chromogranin A (LK2H10) antibody and CD56 (MRQ-42) antibody were comparable with the specificity of the INSM1 (SP493) antibody [91.7% for anti-Chromogranin A (LK2H10) antibody, 90.4% for CD56 (MRQ-42) antibody]. The performance of the anti-Synaptophysin (SP11) antibody was suboptimal, with a sensitivity of 82.9% and a specificity of 87.6%.
conclusionsOverall, our data demonstrate that the IHC assay using the newly developed INSM1 (SP493) antibody is highly specific and sensitive for identifying primary neuroendocrine lung neoplasms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.